Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
Genmab quietly reveals pipeline discontinuations and a delay to the son of Darzalex.
